| Hazard Information | Back Directory | [Uses]
Cusatuzumab (ARGX-110) is a human αCD70 monoclonal antibody. Cusatuzumab has the activity of enhancied antibody-dependent cellular cytotoxicity (ADCC). Cusatuzumab blocks the CD70/CD27 signaling pathway, reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab can be used to study leukemia[1]. | [in vivo]
Cusatuzumab (intraperitoneal injection; 10 mg/kg; 3 times) can reduce leukemia cell colonization and LSC number, and the effect is better in the presence of NK cells in NSG mice[1]. | [References]
[1] Riether C, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020; 26(9):1459-1467. DOI:10.1038/s41591-020-0910-8 |
|
|